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Abstract
Performance of indirect fluorescent antibody (IFA) assays and rapid influenza diagnostic tests (RIDT) during the 2009 H1N1
pandemic was evaluated, along with the relative effects of age and illness severity on test accuracy. Clinicians and
laboratories submitted specimens on patients with respiratory illness to public health from April to mid October 2009 for
polymerase chain reaction (PCR) testing as part of pandemic H1N1 surveillance efforts in Orange County, CA; IFA and RIDT
were performed in clinical settings. Sensitivity and specificity for detection of the 2009 pandemic H1N1 strain, now officially
named influenza A(H1N1)pdm09, were calculated for 638 specimens. Overall, approximately 30% of IFA tests and RIDTs
tested by PCR were falsely negative (sensitivity 71% and 69%, respectively). Sensitivity of RIDT ranged from 45% to 84%
depending on severity and age of patients. In hospitalized children, sensitivity of IFA (75%) was similar to RIDT (84%).
Specificity of tests performed on hospitalized children was 94% for IFA and 80% for RIDT. Overall sensitivity of RIDT in this
study was comparable to previously published studies on pandemic H1N1 influenza and sensitivity of IFA was similar to
what has been reported in children for seasonal influenza. Both diagnostic tests produced a high number of false negatives
and should not be used to rule out influenza infection.
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Introduction
Accurate and rapid testing of patients for influenza virus is
important to optimize antiviral use, minimize antibiotic use, and
appropriately isolate hospitalized patients to prevent hospital-
acquired infections. During the 2009 H1N1 pandemic, viral
culture and real-time reverse transcriptase polymerase chain
reaction (rRT-PCR) testing was available through public health
laboratories and later through commercial laboratories. However,
effective clinical management of patients hospitalized with
respiratory illnesses often depends on timeliness of results.
To help with initial diagnosis, many physicians utilized indirect
or direct fluorescent antibody (IFA or DFA, respectively) or rapid
influenza diagnostic tests (RIDT). Results of RIDT procedures are
available within 30 minutes of specimen collection and do not
require laboratory expertise but reported sensitivity during the
initial stages of the pandemic was low. Several studies looking at
RIDT for detection of influenza A(H1N1)pdm09 have shown
sensitivity ranging from 18–69% [1–11]. IFA and DFA tests are
performed in the hospital or reference laboratory and results can
be obtained within two to four hours. Additionally, because IFA
and DFA tests are usually performed as part of a viral respiratory
panel, they are useful for the identification of respiratory viruses
other than influenza. Sensitivity of DFA for the detection of
A(H1N1)pdm09 has been reported between 47 to 93%
[1,3,6,9,11–16]. Information is not currently available on the
accuracy of IFA for the detection of A(H1N1)pdm09 in a clinical
setting, although a newly developed H1N1-specific IFA claims to
have up to 100% sensitivity [17,18]. More information on the
accuracy of IFA tests compared to other diagnostic methods for
the detection of A(H1N1)pdm09 is needed to determine their




During the period of this study, influenza A(H1N1)pdm09
infection was reportable as part of enhanced surveillance in
California. The information collected for this study is consistent
with activities performed during a public health response and did
not require institutional review board approval. Therefore, no
consent was obtained, as the specimens included in this study were
tested as part of public health surveillance. Technical and physical
safeguards to ensure the privacy of protected health information
were followed as required by the Health Insurance Portability and
Accountability Act of 1996, including maintaining electronic files
on secure servers, storing records in locked cabinets and limiting
access to authorized personnel.
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surveillance for human cases of pandemic H1N1 on April 24,
2009. Clinicians and community partners were asked to report
patients with influenza-like illness meeting certain epidemiologic
criteria, which evolved over time based on Centers for Disease
Control and Prevention (CDC) and California Department of
Public Health guidance, and to submit specimens to the Orange
County Public Health Laboratory (OCPHL) for testing. During
the initial stages of the 2009 influenza pandemic, surveillance
focused on case finding activities. Specimens were accepted at
OCPHL if patient had influenza-like illness (ILI), defined as fever
$100uF, cough and/or sore throat, and met one of the following
conditions: (1) had contact with a confirmed case, (2) traveled to
areas with pandemic H1N1 activity in the seven days preceding
illness onset, (3) had contact with someone with ILI who traveled
to areas with pandemic H1N1 activity, (4) had contact with pigs,
(5) was part of a defined cluster or outbreak of people with ILI, or
(6) was hospitalized with ILI or pneumonia. Submission criterion
was revised on June 25, 2010. Patients met the new criteria for
testing if they had ILI, pneumonia or severe, unexplained febrile
respiratory illness, or sepsis-like syndrome (in infants, adults over
64 years of age, or persons with compromised immune systems)
and one of the following: (1) was a health care worker, (2) was
pregnant, (3) was part of a defined cluster or outbreak of people
with ILI, (4) was hospitalized, (5) or lived in an institutional setting.
Testing criteria were revised again on October 2, 2010 to focus on
patients who were hospitalized in the intensive care unit or died
and had unexplained febrile respiratory illness, ILI, pneumonia or
sepsis-like syndrome. Results were included in this analysis if rRT-
PCR was performed through OCPHL; both rRT-PCR and either
IFA and/or RIDT testing were performed for the same patient;
specimens were collected on the same day, and the patient did not
have a positive test for seasonal influenza. Results of 638
specimens collected from April 27 through October 14, 2009,
from 633 patients met these criteria.
Specimen types and testing methods
Specimens were received from hospitalized patients (70%),
emergency room visits (17%), CDC Sentinel Provider Influenza
Surveillance Program sites (10%), and other outpatient visits (3%).
Specimen types were known for 600 specimens and included
nasopharyngeal or nasal swabs (256; 85%) and washes (322; 54%),
tracheal aspirates (18; 3%), bronchoalveolar lavage (3; 0.5%), and
lung tissue (1; 0.2%). The majority (84%) of IFA specimens were
nasal washes and the majority (68%) of RIDT specimens were
nasopharyngeal swabs. Samples were taken at the point-of-care
and initial testing was done onsite or referred to a commercial
laboratory. Additionally, samples were forwarded to OCPHL for
confirmation by rRT-PCR using reagents and protocol provided
by CDC (CDC Swine Influenza Virus Real-time rRT-PCR
Detection Panel). Each hospital supplied viral transport medium
for specimens. Cool packs were used to maintain proper
temperature of specimens during transport to OCPHL. Once
received by OCPHL, specimens were placed in a refrigerator at
4uC62uC, then frozen to 270uC prior to extraction. All
specimens were typed with InfA and InfB primers and probes.
Influenza A positive specimens were sub-typed with seasonal H1
and H3 primers and the CDC Swine Influenza Detection Panel
was used to detect swine flu A and swine H1. All IFA testing was
conducted at a hospital laboratory serving two hospitals using
BartelsH Viral Respiratory Screening and Identification Kit
(Trinity Biotech, PLC, Co Wicklow, Ireland). RIDTs were
performed at a variety of facilities and included QuickVue
Influenza, which does not distinguish between A and B antigens
(Quidel Corporation, San Diego, CA), QuickVue Influenza A+B,
which distinguishes between A and B antigens (Quidel), and
BinaxNOW Influenza A&B test (BinaxNOW; Inverness Medical,
Waltham, MA).
Sensitivity and specificity were calculated using rRT-PCR for
influenza A(H1N1)pdm09 virus as the reference. Test perfor-
mance was determined for children (,18 years of age) and adults
and for hospitalized patients and outpatients. Data was analyzed
using SPSS 16 (SPSS Inc. (IBM), Chicago, IL). Exact Binomial
95% confidence intervals were calculated using JavaStat (http://
statpages.org/confint.html), accessed March 2011.
Results
Results were available for 394 children, 243 adults and 1 person
of unknown age. Overall 245 specimens (38%) were positive for
influenza A(H1N1)pdm09 (139 children/106 adults). There were
438 respiratory specimens taken from hospitalized patients, of
which 131 (30%) were positive for A(H1N1)pdm09 (82 children/
49 adults). Of the 200 specimens from non-hospitalized patients,
114 (57%) were positive for A(H1N1)pdm09 (57 children/57
adults). Median age of patients for whom specimens were included
was 12 years (range: ,1 to 93). The median age for those
specimens with confirmed influenza was 15 years (range: ,1t o
81).
Overall sensitivity of IFA tests and RIDTs was 71% and 69%,
respectively. Very few IFA results were received on adults and on
outpatient children. Figure 1 and Table 1 presents the sensitivity of
RIDT and IFA tests by severity and age. Sensitivity of IFA and
RIDT performed on hospitalized children was 75% and 84%,
respectively. Sensitivity of RIDT for outpatient children was 76%.
In comparison, sensitivity of RIDT performed on adults in
outpatient settings was 75% compared to only 45% for
hospitalized adults. Overall specificity was 91%. Figure 1 and
Table 2 presents the specificity of RIDT and IFA tests by severity
and age. Specificity of tests performed on hospitalized children was
94% for IFA and 80% for RIDT. Specificity for RIDT performed
in pediatric and adult outpatients was 91% and 90%, respectively.
QuickVue Influenza A+B, the most commonly performed RIDT,
had a sensitivity of 69% (CI: 60% to 77%) and a specificity of 96%
(CI:92% to 98%). Due to small numbers, sensitivity and specificity
of QuickVue Influenza (non-A+B) and BinaxNOW A&B RIDTs
are not displayed.
Mean time from illness onset to specimen collection was similar
for hospitalized adults, (2.7 days) and outpatient adults (2.2 days)
and was also similar for hospitalized children (2.8 days) and
outpatient children (2.1 days), p.0.05. Mean age was significantly
higher among hospitalized adults (52 years) compared to
outpatient adults (31 years), p,0.05, and significantly lower
among hospitalized children (5 years) compared to outpatient
children (9 years), p,0.05.
Discussion
To our knowledge, this is the first study to evaluate an IFA for
the diagnosis of influenza A(H1N1)pdm09 in the clinical setting.
There is an IFA specifically for the diagnosis of A(H1N1)pdm09
that was approved by the Food and Drug Administration on an
emergency use authorization basis, but it has only been evaluated
in the lab [17,18]. In hospitalized children, our IFA performed no
better than RIDT. Other investigators looking at DFA and RIDT
have had similar findings [9,16]. Our overall sensitivity of RIDT is
comparable to previous published studies on A(H1N1)pdm09 and
sensitivity of IFA is similar to what has been reported in children
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[19].
In choosing between RIDT and IFA tests, RIDT offers quicker
results with similar sensitivity, requires less experienced personnel
to perform and utilizes less laboratory personnel time and
equipment. However, IFA testing is often performed as part of a
respiratory virus panel and positive results for a different
respiratory virus than influenza would provide useful information
for infection control and other management decisions.
With such a low sensitivity, negative RIDT and IFA test results
must be interpreted with caution. Since these tests produce a high
number of false negative results, clinicians would not be able to
rule out a diagnosis of influenza based on a negative result.
Sensitivity of RIDTs was lower in outpatient children (76%)
compared to hospitalized children (84%) and was especially poor
in hospitalized adults (45%) compared to outpatient adults (75%).
Time from symptom onset to specimen collection was not
significantly different between the various groups. We also looked
at age as a possible factor affecting sensitivity. Hospitalized
children were significantly younger than outpatient children, while
hospitalized adults were significantly older than outpatient adults.
It is well know that children shed more influenza virus and in
greater quantities than adults. However, the effect of age on viral
shedding in adults is less established. Clinicians should be aware
that sensitivity of RIDTs varies greatly and may be poor in older
adults.
The overall specificity of RIDT (91%) is similar to what has
been reported in the literature for influenza A(H1N1)pdm09 (86%
to 100%), however, results among certain subgroups and test types
were much lower than expected [3,4,5,8,11,19,20]. Since RIDT
and IFA tests were performed in the clinical setting and PCR
testing was performed at a different facility, it is possible that some
RIDT and IFA tests were truly positive and the specimens lost
integrity during transport to OCPHL. Given that PCR testing
performed at OCPHL was used as the gold standard for disease
classification, this would result in more false positives then is
accurate due to misclassification of those who had
A(H1N1)pdm09. While our results may be due to small sample
size or loss of specimen integrity during transport, healthcare
providers should be aware that these tests may produce false
positives under certain conditions.
Our study is limited by the lack of detailed information recorded
on specimen type (i.e. nasal swab versus nasopharyngeal swab)
restricting our ability to account for different collection methods in
our analysis. Additionally, in a small number of patients, the
specimen tested by IFA or RIDT may not have been the exact
same specimen tested by rRT-PCR although all specimens were
collected on the same day. One hospital laboratory performed all
IFA testing, while RIDT testing was performed in a variety of
facilities and using different methods. Finally, since IFA and RIDT
were performed at a different facility than rRT-PCR, storage or
transportation issues (including transport temperature) may have
affected the integrity of the sample and are limitations of the study.
In our study, clinically based diagnostic tests for influenza
A(H1N1)pdm09 had variable sensitivities and specificities and may
lead to false negative and false positive results. Treatment and
infection control decisions should not be changed or delayed based
on negative IFA or RIDT results. Research is needed to develop
and validate more sensitive rapid testing for influenza.
Figure 1. Sensitivity of IFA tests and RIDTs for the detection of pandemic H1N1 influenza. Sensitivity was calculated using real-time
reverse transcriptase polymerase chain reaction as the gold standard. IFA results for other groups were not available due to lack of data.
doi:10.1371/journal.pone.0033097.g001
Table 1. Comparison of Sensitivity for RIDT and IFA Tests by Severity and Age using PCR as the Gold Standard.
IFA RIDT
Positive False Negative Sensitivity (95% CI) Positive False Negative Sensitivity (95% CI)
Inpatients Children 43 14 75% (62 to 86) 21 4 84% (64 to 95)
Adults 2 3 ---------------- 20 24 45% (30 to 61)
Outpatients Children 2 2 ---------------- 41 13 76% (62 to 87)
Adults — — ---------------- 43 14 75% (62 to 86)
doi:10.1371/journal.pone.0033097.t001
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